John E Shulze, CTO Biosensors International Inc Drug Application in Stent Technology: How to Diversify? John E Shulze, CTO Biosensors International Inc 1

My Conflicts of interest are: Chief Technology Officer and a shareholder of Biosensors International Inc.1 (1Biosensors’ development pipeline products to be discussed in this Presentation)

BIOLIMUS A9™ DRUG RAPAMYCIN DERIVATIVE Developed specifically for stent application by Biosensors Potent immunosuppressive and anti-inflammatory properties LIPOPHILICITY COMPARISON Highest lipophilic and hydrophobic properties of commercially available limus drugs Mainly localized effects, minimal drug release into bloodstream

ABLUMINAL BIODEGRADABLE COATING The Abluminal Biodegradable Polymer DES ABLUMINAL BIODEGRADABLE COATING Early BMS-like endothelial coverage1 More targeted tissue release Less systemic exposure BIOLIMUS A9™ DRUG Biosensors’ proprietary rapamycin derivative Highest lypophilicity of the common limus drugs1 BIODEGRADABLE PLA Simultaneous PLA biodegradation and BA9™ elution No PLA /BA9™ coating on the stent after 6 to 9months2 10810-000-EN – Rev.01 1 Data on file at Biosensors Intl 2 In vivo testing in porcine model demonstrates abluminal coating is absorbed after 6 to 9 months - Data on file at Biosensors Intl

Trial Design (LEADERS) Stable and ACS Patients Undergoing PCI Assessor-blind 1:1 Randomisation N=1700 Patients 3-year follow-up (N=1,621; 95.0%) BES BioMatrix Flex N=850 SES Cypher Select N=850 1:3 Randomisation Clinical F/U N=640 Angio F/U N=210 Clinical F/U N=640 Angio F/U N=210 1o endpoint: CV death, MI, clinically-indicated TVR (9 months) 2o endpoints: Death, CV death, MI, TLR, TVR Stent thrombosis according to ARC Angiographic study: In-stent % diameter stenosis Late loss, binary restenosis DAPT recommended for 12 month

Primary Endpoint MACE (Cardiac Death, MI and TVR) @ 9 Months 15 pnon-inferiority = 0.003 Cypher® Select™ 10.5% 10 MACE % BioMatrix Flex™ 9.2% 5 1 2 3 4 5 6 7 8 9 Months of Follow-up BioMatrix Flex™ reached its primary endpoint Windecker S. et al., The Lancet 2008; 372 No. 9644: 1163-1173

MACE 3-year HR 0.82 [0.65 to 1.03] P = 0.09* 1-year HR 0.88 [0.66 to 1.17] P = 0.37* 13.0% 15.4% 2-year HR 0.84 [0.65 to 1.08] P = 0.18* BES 20 19.0% SES 15 15.7% 12.1% % 10 10.7% 5 6 12 18 24 30 36 Number at risk BES 857 851 761 743 729 712 668 SES 850 846 749 732 713 686 639 Months *P values for superiority MACE = Cardiac Death, MI, or Clinically-Indicated TVR Serruys, P. W., oral presentation ,TCT 2010

Definite ST through 3 years BES 2.0% 1-year HR 0.99 [0.51 to 1.94] P = 0.98* 2.2% 2.5% 2-year HR 0.90 [0.48 to 1.67 P = 0.73* 3-year HR 0.78 [0.43 to 1.43] P = 0.43* 4.0 SES 1.0 2.0 3.0 2.9% Δ 0.7% % Δ 0.3% 2.2% Δ 0.0% 6 12 18 24 30 36 Months Number at risk BES 857 846 808 797 787 774 732 SES 850 841 801 792 779 758 715 *P values for superiority Serruys P.W., oral presentation, TCT 2010 Footer

PROVISIONAL STENTING USE

Micro-CT Biomatrix results MV STENTING AFTER KISSING

MACE in Complex Patients % Months 8.4% 19.7% 15.9% 6.8% 5 10 15 20 6 12 18 24 36 30 10.0% 21.3% 3-year HR 0.43 [0.23 to 0.84] P = 0.01* 25 STEMI 15.3% 21.8% 18.6% 12.7% 17.0% 23.8% 0.69 [0.46 to 1.04] P = 0.08* High Syntax Score (>16) BES SES Bifurcations % 15.6% 18.9% 16.4% 12.9% 5 10 15 20 6 12 18 24 36 30 18.5% 23.3% 3-year HR 0.79 [0.53 to 1.16] P = 0.22* 25 16.0% 24.1% 0.65 [0.41 to 1.03] P = 0.06* 15.0% 23.5% 17.1% 13.0% Multi-vessel *P values for superiority Windecker, S., oral presentation ,TCT 2010

Grube E., oral presentation, TCT 2010 BioFreedom™ Selectively micro-structured surface holds drug in abluminal surface structures Hypothesis: Polymer-free drug release via porous-eluting stents may reduce late events caused by polymer stent coatings. Potential advantage Avoid long term late adverse effects that might be attributable to the polymer Improved surface integrity since there is no polymer to be sheared or peeled away from the stent struts Possible shorter need of dual antiplatelet therapy Proprietary Highly Lipophilic Limus drug Grube E., oral presentation, TCT 2010

BioFreedom FIM Design BioFreedom FIM 4 Month Angio FU 182 patients First Cohort Second Cohort 12 Month Clinical FU 99% 4 Month Angio FU 75 patients 12 Month Angio FU 107 patients BioFreedom standard dose (BFD SD) N=25 low dose (BFD LD) N=26 TAXUS® Liberté ® N=24 Angio FU 92% BioFreedom standard dose (BFD SD) N=35 low dose (BFD LD) N=36 TAXUS® Liberté ® Angio FU 92% Enrollment Period Sept 2008 – Jan 2009 Enrollment Period Jan 2009 – Jun 2009

12 Month Angiographic FU In-Stent Late Lumen Loss: 2nd Cohort Primary Endpoint Non – inferiority P values P = 0.001 P = 0.21 (mm) N = 31 N = 35 N = 31 Grube E., oral presentation, TCT 2010 All values are presented as median [IQR]

12 Month MACE All Patients (1st + 2nd Cohorts) BFD SD N = 60 BFD LD N = 62 Taxus MACE* (All Death, MI, Emergent Bypass or TLR) 3 (6.1%) 7 (11.6%) 3 (5.5%) All Death 1 (1.8%) 0 (0.0%) MI 1 (1.6%) Q Wave MI Non-Q Wave MI 1 (1.6%)** Emergent Bypass TLR 6 (10.0%) No ST event out to 12 months: ARC defined Definite, Probable or Possible! *Time to first event **In-hospital MI All p values are non significant. Tests were performed for BFD SD vs. Taxus and BFD LD vs. Taxus.

The AXXESS stent The AXXESS stent is a dedicated bifurcation stent Nitinol self explandable stent Using PLA/BA9™ abluminal coating technology 4 references: 3.0 and 3.5 mm in diameter; 11 and 14 mm in lengths 2 models: bifurcation and LM (difference in sizes of the conical shape) The AXXESS stent is associated to a clinical program AXXESS Plus and DIVERGE for de novo bifurcation AXXENT for LM lesion THE AXXESS stent received CE mark in August 2010 Indication: bifurcation AXXESS

Restenosis in DIVERGE Any in-Bifurcation restenosis: 6.4% (9/140 at 9 months) Lowest restenosis rates ever reported in a bifurcation study of any kind Parent Vessel RS 3 pts Side Branch RS 4pts 2 pts Both

What is next?

Sparrow™ Microstent: designed for small vessels The smallest profile drug-eluting stent system in the world 60% smaller than the nearest available coronary stent system. limus drug with a biodegradable polymer matrix Self-expanding ultra-thin Nitinol stent 0.014-inch guidewire delivery system unique “stent-on-the-wire” construction BMS System CE Marking 3/2010 Non-Sterile, reusable, hand-held Power Supply Sterile, Disposable Adapter Delivery System Stent Lead Connection/ Wire Extension TCT 2010

CARE II DESIGN Primary Endpoint: In Stent Late lumen loss @ 8 mo 2 Arm Sub-Set 1:1 randomization Sparrow DES: Sparrow BM 4 Centers CARE II RCT 4:4:3 (80:80:60) Total N=220 + roll in 3 Arm Sub-Set 1:1:1 randomization Sparrow DES: Sparrow BM: Micro-Driver/Driver BM 14 Centers IVUS sub-study (n = 120 @ 7 centers) Sparrow - BM (N=60) Micro-Driver/ Driver Sparrow – DES (~6ug/mm Sirolimus) Sparrow - BM (N=20) Sparrow – DES (~6 ug/mm Sirolimus) Primary Endpoint: In Stent Late lumen loss @ 8 mo Sparrow DES= 80 Sparrow BM = 80 Micro-Driver/Driver = 60 20 20

CARE II 8 month QCA Binary Restenosis (in Lesion) SES Sparrow Stent demonstrated superior in-stent LLL - CARE II Primary Endpoint met (%) P=0.0012 % CMI-SES CMI-BMS Driver Mean (mm) 0.29±0.45 0.86±0.54 0.94±0.39 Range (mm) -0.59-1.28 -0.20-1.89 0.44-2.11 p 0.0001 < 0.0001 n 30 31 25 P=.00006 6.7 45.2 44 CMI-SES (n=30) CMI-BMS (n=31) Driver (n=25) Abiziaid A.C. et al., TCT 2010

*BA9 application under development Take-home message BA9 shows sustained Safety and Efficacy – Independent from stent platform or method of drug delivery! BioMatrixTM BioMatrixTM Flex BioFreedomTM AXXESSTM Plus Sparrow-DES Nobori (Terumo) Custom NXTM (XTENT) Stainless Steel Balloonexpandable Abluminal biodegradable polymer Polymer Free Nitinol Self-expandable Designed for Bifurcations Sirolimus*/PLA Designed for small vessels SS BA9/PLA Cobalt-Chrome *BA9 application under development

BioMatrix Flex™ Drug Eluting Coronary Stent System is CE approved Not available for sale in the United States and certain other countries of Biosensors International group, Ltd. in the United States and other countries BioMatrix Flex, Biolimus A9 and BA9 are trademarks or registered trademarks All cited trademarks are the property of their respective owners © 2011 Biosensors International Group, Ltd. All rights reserved